Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

The approval is based on results from the Phase III MARIPOSA trial (NCT04487080), which compared the combination therapy to ...

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and Lazcluze ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

AstraZeneca's EGFR inhibitor Tagrisso has become the first drug in the class to be approved in the EU as a treatment for a specific form of locally advanced, unresectable non-small cell lung ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...

AstraZeneca has gained approval from the European Commission (EC) for its oral therapy, Tagrisso (osimertinib), to treat adults with locally advanced, unresectable non-small cell lung cancer (NSCLC).

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

Chinese regulators have accepted HUTCHMED's (NASDAQ:HCM) application for priority review for the drug combination Orpathys and Tagrisso in the treatment of certain patients with EGFR-positive non ...

In terms of this drug being used to target patients with EGFR mutant non-small cell lung cancer [NSCLC], the goal is to overcome resistance observed with TAGRISSO [osimertinib] from AstraZeneca (AZN).